Y-mAbs Therapeutics Inc (NAS:YMAB)
$ 12.18 -0.55 (-4.32%) Market Cap: 534.93 Mil Enterprise Value: 484.06 Mil PE Ratio: 0 PB Ratio: 5.39 GF Score: 56/100

Y-mAbs Therapeutics Inc Research And Development Day (Virtual) Transcript

Dec 15, 2021 / 05:00PM GMT
Release Date Price: $16.6 (+5.53%)
Operator

Good afternoon, and welcome to the Y-mAbs Therapeutics Virtual R&D Day. (Operator Instructions)

I'd now like to turn the call over to Thomas Gad, President and Founder of Y-mAbs Therapeutics. Please go ahead, Thomas.

Thomas Gad
Y-mAbs Therapeutics, Inc. - Founder, Chairman, President and Head of Business Development & Strategy

Thank you, Sarah, and thank you, everyone, for joining us today at our third annual R&D Day. We have a very exciting lineup of speakers today, starting with Dr. Oesterheld from Levine in North Carolina, who's going to present on the current treatment landscape of DANYELZA today, followed by Dr. Mora from Barcelona, who's going to show us some exciting those in experience with DANYELZA on patients with high-risk neuroblastoma. We will hear from Dr. Rajah, who is our Chief Medical Officer, how that new dosing experience plays into our strategy with DANYELZA going forward.

And we will hear from Dr. Steen Lisby, our Chief Scientific Officer, on an update on our very exciting platform, SADA; and Claus Moller,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot